Correspondence: D. Campana, M.D. Ph.D., Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis TN 38105, USA.
This work was supported by grants CA60419 and CA21765 from the National Cancer Institute, and by the American Lebanese Syrian Associated Charities (ALSAC).
July 2009
I. Introduction
In patients with acute lymphoblastic leukemia (ALL), the degree of treatment
response guides clinical decisions, and information about this response is essential
for selecting the optimal clinical management approach. Unfortunately, determining
whether residual leukemia is present during treatment by traditional methods,
i.e. the morphologic examination of cells in bone marrow smears, is typically
a subjective and imprecise endeavor owing to the fact that the morphology of
ALL cells is very similar to that of normal bone marrow cell subpopulations,
such as immature B cells and activated mature lymphocytes. Hence, the remission
status of patients with ALL often raises doubt in the mind of pathologists and
clinicians; this uncertainty can lead to overtreatment (and excessive toxicities)
or undertreatment (and increased risk of relapse). The advent of methods for
detecting minimal residual disease (MRD) has revealed that many patients considered
to be in "remission" by morphologic analysis still have substantial
amounts of residual leukemia (Campana, 2008a). Because of the strong correlation
between MRD levels and treatment outcome, MRD testing is increasingly being
incorporated in clinical trials.
II. A brief review of methods for MRD detection
Polymerase chain reaction
Two main types of molecular targets can be used to identify leukemic cells.
One is represented by clonally rearranged antigen-receptor genes, i.e, immunoglobulin
(IG) and T-cell receptor (TCR) genes. The junctional regions of the rearranged
genes are unique to the leukemic clone. Typically, the unique gene signature
is identified at diagnosis in each case using PCR primers matched to the V and
J regions of various IG and TCR genes. If a rearrangement is found, the PCR
product is further analyzed to ensure its clonal origin by using heteroduplex
analysis (van der Velden et al., 2007). The junctional regions of the IG/TCR
gene rearrangements are then sequenced to design specific oligonucleotides which
are then applied to monitor MRD (van der Velden et al., 2007). Investigators
have developed methods to detect clonal IG/TCR gene rearrangements without the
need for patient-specific oligonucleotides. These efforts have relied on high-resolution
electrophoresis, such as radioactive fingerprinting or fluorescent gene scanning,
but this approach has a considerably lower sensitivity, usually not better than
0.1%, and date interpretation may be difficult (Delabesse et al., 2000; Knechtli
et al., 1998).
Because the majority of B-lineage ALL cases have IG (Beishuizen et al., 1993)
and cross-lineage TCR gene rearrangements (Szczepanski et al., 1999a), MRD monitoring
by using these genes as targets is feasible in > 90% of cases of B-lineage
ALL. Likewise, TCR genes are rearranged in most cases of T-lineage ALL and cross-lineage
IG gene rearrangements occur in approximately 20% of T-ALL (Szczepanski et al.,
2000; Kneba et al., 1995). In sum, the method can be used to monitor MRD in
most cases of childhood and adult ALL (van der Velden et al., 2003; van der
Velden et al., 2007; Bruggemann et al., 2006; Flohr et al., 2008).
Detection of MRD by PCR using IG/TCR gene rearrangements is most frequently
performed by using "real-time" quantitative PCR (RQ-PCR) (van der
Velden et al., 2003) and less commonly by limiting dilution (Neale et al., 1999).
Because rearranged IG and TCR genes are present in one copy per cells, very
precise estimates of the MRD levels can be achieved. IG and TCR genes may be
affected by continuing or secondary rearrangements (Szczepanski et al., 1999b),
resulting in subclones with distinct clonal IG/TCR gene rearrangements, and
minor clones at diagnosis may become predominant at relapse (Szczepanski et
al., 2002; van der Velden et al., 2004). These possibilities have prompted the
recommendation of targeting two or more different rearrangements during MRD
studies (van der Velden et al., 2007). Multiple targets are identifiable in
the majority of ALL cases although in approximately 30% of cases it is not possible
to identify multiple targets that allow detection of MRD with a high sensitivity
(e.g., 0.01%) (Pongers-Willemse et al., 1999; Flohr et al., 2008).
The second type of gene target for MRD monitoring by PCR is represented by gene
fusions, such as BCR-ABL1, MLL-AFF1, TCF3-PBX1, and ETV6-RUNX1, and their resulting
aberrant mRNA transcripts (van Dongen et al., 1999; Gabert et al., 2003). Recurrent
fusions are identified in less than half of patients with newly diagnosed ALL
(Gabert et al., 2003), thus limiting the applicability of this approach. However,
with the systematic use of novel whole-genome screening technologies (Mullighan
et al., 2007; Mullighan et al., 2009), it is very likely that additional genetic
targets will enrich the available array of gene targets for MRD studies.
One potential advantage of using fusion transcripts to monitor MRD is that it
might be possible to detect pre-leukemic cells (Hong et al., 2008). If so, the
clinical significance of such finding needs to be investigated. A clear disadvantage
of using fusion transcripts as targets is an accurate estimate of the number
of leukemic cells present in the sample is difficult. This is because that ratio
between amount of PCR product and target cell number is uncertain, there may
be interpatient variability in the number of transcripts per leukemic cell within
the same genetic subtype of ALL, and this number could be altered by chemotherapy
(Gabert et al., 2003).
Flow cytometry
Immunophenotypes characteristic of leukemic cells can be used to distinguish
ALL from normal cells by flow cytometry (Campana, 2008). There are three main
categories of leukemia-associate immunophenotypes. One is characterized by the
expression of fusion proteins derived from fusion transcripts, such as BCR-ABL1,
ETV6-RUNX1, or TCF3-PBX1. However, suitable antibodies for reliable flow cytometric
analysis of these proteins are lacking. A second group is represented by the
immunophenotype of T-lineage ALL cells, which is normally expressed only by
a subset of thymocytes and it is not expressed by cells outside the thymus.
Immature T-cell phenotypes can be effectively used to monitor MRD in T-lineage
ALL (Coustan-Smith et al., 2002a), and also to detect disease dissemination
in T-cell lymphoblastic lymphoma (Coustan-Smith et al., 2009a). The third group
of leukemia-associated immunophenotype is constituted by multiple marker combinations
that are found in B-lineage ALL cells but are normally not expressed during
lympho-hematopoiesis. The use of these immunophenotypes, named "asynchronous"
or "aberrant" (Hurwitz et al., 1988; Lucio et al., 1999; Campana
and Coustan-Smith, 1999; Ciudad et al., 1998), requires a particularly good
knowledge of the immunophenotypes expressed by normal hematopoietic cells, in
both normal and recovering bone marrow.
Leukemia-associated immunophenotypes that are suitable for MRD studies and afford
a sensitivity of at least 0.01% can be identified in nearly all patients with
ALL (Coustan-Smith et al., 2002b; Campana and Coustan-Smith, 1999). Results
obtained by flow cytometry are very similar to those obtained by PCR amplification
of IG/TCR genes, if MRD is present at a ≥ 0.01% level (Neale et al., 1999; Neale
et al., 2004; Kerst et al., 2005).
Current methods for MRD testing by flow cytometry typically require the use
of extensive antibody panels and considerable interpretative expertise. We developed
a simplified flow cytometric MRD test that can detect residual B-lineage ALL
cells (which express CD19 plus CD10 and/or CD34) on day 15-26 of treatment with
a minimum panel of antibodies (Coustan-Smith et al., 2006). The rationale for
this strategy is that normal immature CD19+ cells, or those expressing CD10
and/or CD34, are consistently undetectable in bone marrow samples collected
from children with T-lineage ALL after 2 weeks of remission induction chemotherapy,
because of their high sensitivity to glucocorticoids and other antileukemic
drugs. We therefore reasoned that any cell with this immunophenotype detected
in patients with B-lineage ALL on day 19 of induction treatment would likely
be residual leukemic cells. Indeed, our findings indicate that the results of
the simplified test correlate very well with those of more complex flow cytometric
assays or PCR amplification of IGH/TCR genes. It should be stressed that this
test cannot be used beyond this early treatment interval because of the high
risk of false-positive results in recovering marrow samples.
III. Results of correlative studies with treatment outcome
Studies in pediatric ALL
The clinical significance of MRD testing during the initial phases of treatment
was definitively demonstrated by 3 prospective studies published in 1998 by
the EORTC (Cave et al., 1998), St Jude (Coustan-Smith et al., 1998) and BFM
groups (van Dongen et al., 1998). The results these studies consolidated those
of many other previous reports of smaller series, and have been confirmed by
several subsequent studies (reviewed in Campana, 2009). MRD testing is also
clinically informative for patients with specific ALL subtypes (Coustan-Smith
et al., 2000; Biondi et al., 2000; Attarbaschi et al., 2008; van der Velden
et al., 2009), patients with relapsed ALL who achieve a second remission (Eckert
et al., 2001; Coustan-Smith et al., 2004; Paganin et al., 2008), patients with
extramedullary relapse (Hagedorn et al., 2007) and patients undergoing allogeneic
hematopoietic stem cell transplantation (Knechtli et al., 1998; van der Velden
et al., 2001; Bader et al., 2002; Uzunel et al., 2001; Krejci et al., 2003;
Goulden et al., 2003).
Levels of MRD are directly proportional to the risk of subsequent relapse. Thus,
MRD ≥ 1% at the end of remission induction therapy predicted an extremely
high rate of relapse in St Jude studies (Coustan-Smith et al., 2000), while
MRD ≥ 0.1% on both day 33 and day 78 of treatment had a very high risk of
relapse in the I-BFM Study Group studies (van Dongen et al., 1998; Flohr et
al., 2008). The threshold level commonly used to define MRD positivity is 0.01%
of bone marrow mononuclear cells. Patients with ≥ 0.01% MRD at any time point
during treatment had a higher risk of relapse in earlier St Jude studies (Coustan-Smith
et al., 1998; Coustan-Smith et al., 2000; Coustan-Smith et al., 2002b), as had
those with ≥ 0.01% MRD on day 29 of treatment in studies of the Children's
Oncology Group (Borowitz et al., 2008). In other studies, however, a threshold
of 0.1% appeared to be more informative (Cave et al., 1998; Dworzak et al.,
2002; Zhou et al., 2007).
In addition to providing a parameter to identify patients at a higher risk of
relapse, MRD can also identify patients with excellent early treatment response
and undetectable (< 0.01%) MRD after 2-3 weeks of therapy. We found that
183 of 402 (45.5%) B-lineage ALL patients were MRD < 0.01% on day 19 of treatment
(Campana, 2008b), a feature that is associated with excellent prognosis overall
(Panzer-Grumayer et al., 2000; Coustan-Smith et al., 2002b).
The prevalence of MRD differs among different genetic subtypes of childhood
ALL (Pui et al., 2001; Borowitz et al., 2003). Thus, MRD is generally more prevalent
among patients with BCR-ABL1 ALL and less prevalent among those with ETV6-RUNX1,
hyperdiploid (> 50 chromosomes) and TCF3-PBX1 ALL (Campana, 2008c). More
recently, it has been shown that patients with B-lineage ALL and mutations or
deletions of the Ikaros (lIKZF1) gene had a higher prevalence
of MRD during remission induction therapy than those without this abnormality
(Mullighan et al., 2009). In addition, among patients with T-lineage ALL, MRD-positive
findings were strikingly more frequent and levels higher in the subgroup of
patients with early thymic precursor (ETP)-ALL (Coustan-Smith et al., 2009b).
MRD studies have now been included in clinical trials to guide therapy. Thus,
the AIEOP-BFM group uses MRD to classify patients with newly diagnosed ALL into
three risk groups: standard risk (MRD negative on days 33 and 78), intermediate
risk (any MRD positivity on days 33 and 78 but < 0.1% on day 78) and high
risk (MRD ≥ 0.1% on day 78) (Flohr et al., 2008). In the AIEOP-BFM ALL 2000
trial, of the 3341 diagnostic samples examined, 88 (3%) lacked suitable gene
rearrangements targets for PCR analysis, and an additional 217 (7%) had a target
but not sufficient to reach a sensitivity of 0.01% (Flohr et al., 2008). At
least two sensitive gene rearrangement targets could be identified in 71% of
patients. Adequate data for MRD-based stratification were obtained in 2594 (78%)
of the 3341 patients (78%).
In the St Jude Total XV trial for children with newly diagnosed ALL, our laboratory
monitored MRD by using flow cytometric detection of aberrant immunophenotypes
and/or PCR amplification of antigen-receptor genes (Pui et al., 2009). Overall,
482 of 492 patients (98%) were monitored by flow cytometry and 403 of 492 (82%)
by PCR (applied only to patients with B-lineage ALL). As previously shown (Neale
et al., 1999; Neale et al., 2004; Kerst et al., 2005), both methods yielded
virtually identical results above the threshold level of 0.01%. The two methods
in combination could be applied to study 491 of 492 patients (99.8%) (Pui et
al., 2009). The single patient with no available immunophenotypic or antigen-receptor
gene rearrangements had a MLL-AF9 fusion transcript and was monitored by RQ-PCR
using that marker. In our current Total XVI trial, patients with MRD ≥ 1%
on day 15 receive intensified remission induction therapy; further intensification
is reserved for patients with ≥ 5% leukemic cells. By contrast, patients
with MRD < 0.01% on day 15 receive less intensive reinduction therapy and
lower cumulative doses of anthracyclin. Patients with standard-risk ALL who
have MRD of ≥ 0.01% on day 42 are reclassified as high-risk; patients with
MRD ≥ 1% are eligible for transplant in first remission. Because in patients
with T-lineage ALL MRD levels in peripheral blood are similar to those in bone
marrow (Coustan-Smith et al., 2002a; van der Velden et al., 2002), it is our
current practice to use blood instead of marrow to monitor MRD after day 42
in these patients.
Studies in adult ALL
Several studies have also demonstrated the prognostic importance of MRD in adult
ALL patients (Mortuza et al., 2002; Bruggemann et al., 2006; Raff et al., 2007;
Holowiecki et al., 2008; Bassan et al., 2009). Bruggeman et al. (Bruggemann
et al., 2006) studied MRD in 196 standard-risk patients using PCR amplification
of antigen-receptor genes and segregated three groups: 10% of patients had <
0.01% MRD on days 11 and 24 of treatment and 23% had persistent MRD ≥ 0.01%
until week 16. The 3-year relapse rates were 0% and 94%; for the remaining patients,
the relapse rate was 47%. The same group subsequently studied post-consolidation
samples from 105 patients who were in hematologic remission, had completed the
first-year chemotherapy, and were MRD-negative before enrolling in the study.
MRD was detected in 28 patients, 17 of whom relapsed. By contrast, 77 patients
remained MRD-negative and only 5 relapsed (Raff et al., 2007). Using IG/TCR
gene rearrangements or fusion transcripts as targets, Bassan et al. (Bassan
et al., 2009) measured MRD at the end of consolidation. Five-year overall disease-free
survival estimates were 72% among 58 MRD negative patients and 14% among the
54 patients with positive MRD. In a study using flow cytometry, Holowiecki et
al. (Holowiecki et al., 2008) measured MRD in 116 patients with Philadelphia-negative
ALL and found that MRD ≥ 0.1% after remission induction therapy was an independent
predictor for relapse. Together, the results of these studies provide convincing
evidence of the clinical significance of MRD in adult ALL, although the strengths
of the correlations with outcome depend on the subgroup of patients studied
and the type of treatment.
Monitoring of MRD in adult patients with Philadelphia-positive ALL receiving
transplant and/or imatinib therapy has been shown to predict treatment outcome
(Radich et al., 1997; Wassmann et al., 2005; Pane et al., 2005). It has been
shown that MRD detected before initiation of conditioning is a significant predictor
of failure post-transplant (Sanchez et al., 2002; Spinelli et al., 2007).
Areas for further research
Measuring MRD provides unprecedented insights into the kinetics of treatment
response in patients with acute leukemia which not only have prognostic ramifications
but can also provide novel endpoints for correlative studies with cellular and
biologic features. For example, the correlation between MRD and gene expression
of leukemic lymphoblasts at diagnosis revealed genes associated with treatment
response (Cario et al., 2005; Flotho et al., 2006; Flotho et al., 2007), while
correlations with gene polymorphisms has pointed to drug-metabolizing molecules
which may have a direct impact on leukemia response to treatment (Rocha et al.,
2005; Yang et al., 2009). These areas are clearly worthy of further research,
which may lead to the identification of new prognostic factors and provide clues
about targets for molecular therapies.
Although MRD can be studied in virtually all patients with ALL using molecular
and/or flow cytometric methods, MRD assays require considerable expertise and
can be performed well only in specialized centers. Simplification of the methodologies
to widen the applicability of MRD testing should be an objective for future
research. At the same time, increasingly sophisticated methodologies provide
new opportunities for investigation. To this end, the availability of reliable
flow cytometers that can detect 6 or more fluorochromes together with the a
wide array of commercial antibodies open the possibility to investigate the
biologic features of the leukemic cells that contribute to MRD in extraordinary
detail. In turn, such studies should help unearthing some of the biologic roots
of drug resistance in ALL and ultimately lead to more effective and less toxic
treatment.
| Bibliography |
| Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. |
| Hurwitz CA, Loken MR, Graham ML, Karp JE, Borowitz MJ, Pullen DJ, Civin CI. |
| Blood. 1988 Jul;72(1):299-307. |
| PMID 3291983 |
| Detection of immunoglobulin heavy-chain gene rearrangements by Southern blot analysis: recommendations for optimal results. |
| Beishuizen A, Verhoeven MA, Mol EJ, Breit TM, Wolvers-Tettero IL, van Dongen JJ. |
| Leukemia. 1993 Dec;7(12):2045-53. |
| PMID 7902888 |
| Analysis of rearranged T-cell receptor beta-chain genes by polymerase chain reaction (PCR) DNA sequencing and automated high resolution PCR fragment analysis. |
| Kneba M, Bolz I, Linke B, Hiddemann W. |
| Blood. 1995 Nov 15;86(10):3930-7. |
| PMID 7579363 |
| Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. |
| Radich J, Gehly G, Lee A, Avery R, Bryant E, Edmands S, Gooley T, Kessler P, Kirk J, Ladne P, Thomas ED, Appelbaum FR. |
| Blood. 1997 Apr 1;89(7):2602-9. |
| PMID 9116308 |
| Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. |
| Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E. |
| N Engl J Med. 1998 Aug 27;339(9):591-8. |
| PMID 9718378 |
| Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. |
| Ciudad J, San Miguel JF, Lopez-Berges MC, Vidriales B, Valverde B, Ocqueteau M, Mateos G, Caballero MD, Hernandez J, Moro MJ, Mateos MV, Orfao A. |
| J Clin Oncol. 1998 Dec;16(12):3774-81. |
| PMID 9850021 |
| Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. |
| Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, Rubnitz JE, Rivera GK, Sandlund JT, Pui CH, Campana D. |
| Lancet. 1998 Feb 21;351(9102):550-4. |
| PMID 9492773 |
| Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. |
| Knechtli CJ, Goulden NJ, Hancock JP, Grandage VL, Harris EL, Garland RJ, Jones CG, Rowbottom AW, Hunt LP, Green AF, Clarke E, Lankester AW, Cornish JM, Pamphilon DH, Steward CG, Oakhill A. |
| Blood. 1998 Dec 1;92(11):4072-9. |
| PMID 9834212 |
| Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. |
| van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR. |
| Lancet. 1998 Nov 28;352(9142):1731-8. |
| PMID 9848348 |
| Detection of minimal residual disease in acute leukemia by flow cytometry. |
| Campana D, Coustan-Smith E. |
| Cytometry. 1999 Aug 15;38(4):139-52. |
| PMID 10440852 |
| Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. |
| Lucio P, Parreira A, van den Beemd MW, van Lochem EG, van Wering ER, Baars E, Porwit-MacDonald A, Bjorklund E, Gaipa G, Biondi A, Orfao A, Janossy G, van Dongen JJ, San Miguel JF. |
| Leukemia. 1999 Mar;13(3):419-27. |
| PMID 10086733 |
| Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. |
| Neale GA, Coustan-Smith E, Pan Q, Chen X, Gruhn B, Stow P, Behm FG, Pui CH, Campana D. |
| Leukemia. 1999 Aug;13(8):1221-6. |
| PMID 10450750 |
| Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. |
| Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, Pisa P, Gonzalez M, Bartram CR, Panzer-Grumayer ER, Biondi A, San Miguel JF, van Dongen JJ. |
| Leukemia. 1999 Jan;13(1):110-8. |
| PMID 10049045 |
| Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease. |
| Szczepanski T, Beishuizen A, Pongers-Willemse MJ, Hahlen K, Van Wering ER, Wijkhuijs AJ, Tibbe GJ, De Bruijn MA, Van Dongen JJ. |
| Leukemia. 1999a Feb;13(2):196-205. |
| PMID 10025893 |
| Unusual immunoglobulin and T-cell receptor gene rearrangement patterns in acute lymphoblastic leukemias. |
| Szczepanski T, Pongers-Willemse MJ, Langerak AW, van Dongen JJ. |
| Curr Top Microbiol Immunol. 1999b;246:205-13 |
| PMID 10396058 |
| Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. |
| van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Parreira A, Gameiro P, Diaz MG, Malec M, Langerak AW, San Miguel JF, Biondi A. |
| Leukemia. 1999 Dec;13(12):1901-28. |
| PMID 10602411 |
| Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. |
| Biondi A, Valsecchi MG, Seriu T, D'Aniello E, Willemse MJ, Fasching K, Pannunzio A, Gadner H, Schrappe M, Kamps WA, Bartram CR, van Dongen JJ, Panzer-Grumayer ER. |
| Leukemia. 2000 Nov;14(11):1939-43. |
| PMID 11069029 |
| Rapid, multifluorescent TCRG Vgamma and Jgamma typing: application to T cell acute lymphoblastic leukemia and to the detection of minor clonal populations. |
| Delabesse E, Burtin ML, Millien C, Madonik A, Arnulf B, Beldjord K, Valensi F, Macintyre EA. |
| Leukemia. 2000 Jun;14(6):1143-52. |
| PMID 10865981 |
| Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. |
| Panzer-Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H. |
| Blood. 2000 Feb 1;95(3):790-4. |
| PMID 10648387 |
| Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. |
| Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, Sandlund JT, Rivera GK, Rubnitz JE, Ribeiro RC, Pui CH, Campana D. |
| Blood. 2000 Oct 15;96(8):2691-6. |
| PMID 11023499 |
| T cell receptor gamma (TCRG) gene rearrangements in T cell acute lymphoblastic leukemia refelct 'end-stage' recombinations: implications for minimal residual disease monitoring. |
| Szczepanski T, Langerak AW, Willemse MJ, Wolvers-Tettero IL, van Wering ER, van Dongen JJ. |
| Leukemia. 2000 Jul;14(7):1208-14. |
| PMID 10914544 |
| Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. |
| Eckert C, Biondi A, Seeger K, Cazzaniga G, Hartmann R, Beyermann B, Pogodda M, Proba J, Henze G. |
| Lancet. 2001 Oct 13;358(9289):1239-41. |
| PMID 11675066 |
| Childhood acute lymphoblastic leukaemia--current status and future perspectives. |
| Pui CH, Campana D, Evans WE. |
| Lancet Oncol. 2001 Oct;2(10):597-607. |
| PMID 11902549 |
| The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. |
| Uzunel M, Mattsson J, Jaksch M, Remberger M, Ringden O. |
| Blood. 2001 Sep 15;98(6):1982-4. |
| PMID 11535539 |
| Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. |
| van der Velden VH, Joosten SA, Willemse MJ, van Wering ER, Lankester AW, van Dongen JJ, Hoogerbrugge PM. |
| Leukemia. 2001 Sep;15(9):1485-7. |
| PMID 11516112 |
| Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. |
| Coustan-Smith E, Sancho J, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Pui CH, Campana D. |
| Blood. 2002a Oct 1;100(7):2399-402. |
| PMID 12239148 |
| Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. |
| Coustan-Smith E, Sancho J, Behm FG, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Pui CH, Campana D. |
| Blood. 2002b Jul 1;100(1):52-8. |
| PMID 12070008 |
| Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. |
| Bader P, Hancock J, Kreyenberg H, Goulden NJ, Niethammer D, Oakhill A, Steward CG, Handgretinger R, Beck JF, Klingebiel T. |
| Leukemia. 2002 Sep;16(9):1668-72. |
| PMID 12200679 |
| Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. |
| Dworzak MN, Froschl G, Printz D, Mann G, Potschger U, Muhlegger N, Fritsch G, Gadner H; Austrian Berlin-Frankfurt-Munster Study Group. |
| Blood. 2002 Mar 15;99(6):1952-8. |
| PMID 11877265 |
| Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. |
| Mortuza FY, Papaioannou M, Moreira IM, Coyle LA, Gameiro P, Gandini D, Prentice HG, Goldstone A, Hoffbrand AV, Foroni L. |
| J Clin Oncol. 2002 Feb 15;20(4):1094-104. |
| PMID 11844835 |
| Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. |
| Sanchez J, Serrano J, Gomez P, Martinez F, Martin C, Madero L, Herrera C, Garcia JM, Casano J, Torres A. |
| Br J Haematol. 2002 Mar;116(3):686-94. |
| PMID 11849234 |
| Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. |
| Szczepanski T, Willemse MJ, Brinkhof B, van Wering ER, van der Burg M, van Dongen JJ. |
| Blood. 2002 Apr 1;99(7):2315-23. |
| PMID 11895762 |
| Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. |
| van der Velden VH, Jacobs DC, Wijkhuijs AJ, Comans-Bitter WM, Willemse MJ, Hahlen K, Kamps WA, van Wering ER, van Dongen JJ. |
| Leukemia. 2002 Aug;16(8):1432-6. |
| PMID 12145681 |
| Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study. |
| Borowitz MJ, Pullen DJ, Shuster JJ, Viswanatha D, Montgomery K, Willman CL, Camitta B. |
| Leukemia. 2003 Aug;17(8):1566-72. |
| PMID 12886244 |
| Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. |
| Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G, van Dongen JJ. |
| Leukemia. 2003 Dec;17(12):2318-57. |
| PMID 14562125 |
| Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. |
| Goulden N, Bader P, Van Der Velden V, Moppett J, Schilham M, Masden HO, Krejci O, Kreyenberg H, Lankester A, Revesz T, Klingebiel T, Van Dongen J. |
| Br J Haematol. 2003 Jul;122(1):24-9. |
| PMID 12823342 |
| Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group. |
| Krejci O, van der Velden VH, Bader P, Kreyenberg H, Goulden N, Hancock J, Schilham MW, Lankester A, Revesz T, Klingebiel T, van Dongen JJ. |
| Bone Marrow Transplant. 2003 Oct;32(8):849-51. |
| PMID 14520434 |
| Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. |
| van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. |
| Leukemia. 2003 Jun;17(6):1013-34. |
| PMID 12764363 |
| Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. |
| Coustan-Smith E, Gajjar A, Hijiya N, Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Andreansky M, Hancock ML, Pui CH, Campana D. |
| Leukemia. 2004 Mar;18(3):499-504. |
| PMID 14981525 |
| Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. |
| Neale GA, Coustan-Smith E, Stow P, Pan Q, Chen X, Pui CH, Campana D. |
| Leukemia. 2004 May;18(5):934-8. |
| PMID 15029212 |
| TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse. |
| van der Velden VH, Bruggemann M, Hoogeveen PG, de Bie M, Hart PG, Raff T, Pfeifer H, Luschen S, Szczepanski T, van Wering ER, Kneba M, van Dongen JJ. |
| Leukemia. 2004 Dec;18(12):1971-80. |
| PMID 15470492 |
| Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. |
| Cario G, Stanulla M, Fine BM, Teuffel O, Neuhoff NV, Schrauder A, Flohr T, Schafer BW, Bartram CR, Welte K, Schlegelberger B, Schrappe M. |
| Blood. 2005 Jan 15;105(2):821-6. Epub 2004 Sep 23. |
| PMID 15388585 |
| Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. |
| Kerst G, Kreyenberg H, Roth C, Well C, Dietz K, Coustan-Smith E, Campana D, Koscielniak E, Niemeyer C, Schlegel PG, Muller I, Niethammer D, Bader P. |
| Br J Haematol. 2005 Mar;128(6):774-82. |
| PMID 15755280 |
| Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. |
| Pane F, Cimino G, Izzo B, Camera A, Vitale A, Quintarelli C, Picardi M, Specchia G, Mancini M, Cuneo A, Mecucci C, Martinelli G, Saglio G, Rotoli B, Mandelli F, Salvatore F, Foa R. |
| Leukemia. 2005 Apr;19(4):628-35. |
| PMID 15744351 |
| Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. |
| Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH, Sandlund JT, Rubnitz J, Ribeiro R, Campana D, Pui CH, Evans WE, Relling MV. |
| Blood. 2005 Jun 15;105(12):4752-8. Epub 2005 Feb 15. |
| PMID 15713801 |
| Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). |
| Wassmann B, Pfeifer H, Stadler M, Bornhauser M, Bug G, Scheuring UJ, Bruck P, Stelljes M, Schwerdtfeger R, Basara N, Perz J, Bunjes D, Ledderose G, Mahlberg R, Binckebanck A, Gschaidmeier H, Hoelzer D, Ottmann OG. |
| Blood. 2005 Jul 15;106(2):458-63. Epub 2005 Apr 7. |
| PMID 15817679 |
| A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. |
| Coustan-Smith E, Ribeiro RC, Stow P, Zhou Y, Pui CH, Rivera GK, Pedrosa F, Campana D. |
| Blood. 2006 Jul 1;108(1):97-102. Epub 2006 Mar 14. |
| PMID 16537802 |
| Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. |
| Bruggemann M, Raff T, Flohr T, Gokbuget N, Nakao M, Droese J, Luschen S, Pott C, Ritgen M, Scheuring U, Horst HA, Thiel E, Hoelzer D, Bartram CR, Kneba M. |
| Blood. 2006 Feb 1;107(3):1116-23. Epub 2005 Sep 29. |
| PMID 16195338 |
| Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. |
| Flotho C, Coustan-Smith E, Pei D, Iwamoto S, Song G, Cheng C, Pui CH, Downing JR, Campana D. |
| Blood. 2006 Aug 1;108(3):1050-7. Epub 2006 Apr 20. |
| PMID 16627760 |
| A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. |
| Flotho C, Coustan-Smith E, Pei D, Cheng C, Song G, Pui CH, Downing JR, Campana D. |
| Blood. 2007 Aug 15;110(4):1271-7. Epub 2007 Apr 24. |
| PMID 17456722 |
| Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group. |
| Hagedorn N, Acquaviva C, Fronkova E, von SA, Barth A, zur SU, Schrauder A, Trka J, Gaspar N, Seeger K, Henze G, Cave H, Eckert C. |
| Blood. 2007 Dec 1;110(12):4022-9. Epub 2007 Aug 24. |
| PMID 17720883 |
| Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. |
| Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds SB, Su X, Pui CH, Relling MV, Evans WE, Shurtleff SA, Downing JR. |
| Nature. 2007 Apr 12;446(7137):758-64. |
| PMID 17344859 |
| Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. |
| Spinelli O, Peruta B, Tosi M, Guerini V, Salvi A, Zanotti MC, Oldani E, Grassi A, Intermesoli T, Mico C, Rossi G, Fabris P, Lambertenghi-Deliliers G, Angelucci E, Barbui T, Bassan R, Rambaldi A. |
| Haematologica. 2007 May;92(5):612-8. |
| PMID 17488684 |
| Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. |
| Raff T, Gokbuget N, Luschen S, Reutzel R, Ritgen M, Irmer S, Bottcher S, Horst HA, Kneba M, Hoelzer D, Bruggemann M. |
| lood. 2007 Feb 1;109(3):910-5. Epub 2006 Oct 5. |
| PMID 17023577 |
| Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. |
| van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, van der Schoot CE, van Dongen JJ. |
| Leukemia. 2007 Apr;21(4):604-11. Epub 2007 Feb 8. |
| PMID 17287850 |
| Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. |
| Zhou J, Goldwasser MA, Li A, Dahlberg SE, Neuberg D, Wang H, Dalton V, McBride KD, Sallan SE, Silverman LB, Gribben JG. |
| Blood. 2007 Sep 1;110(5):1607-11. Epub 2007 May 7. |
| PMID 17485550 |
| Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. |
| Attarbaschi A, Mann G, Panzer-Grumayer R, Rottgers S, Steiner M, Konig M, Csinady E, Dworzak MN, Seidel M, Janousek D, Moricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA. |
| J Clin Oncol. 2008 Jun 20;26(18):3046-50. |
| PMID 18565891 |
| Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. |
| Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, Linda S, Martin PL, Pullen DJ, Viswanatha DS, Willman CL, Winick N, Camitta BM. |
| Blood. 2008 Jun 15;111(12):5477-85. Epub 2008 Apr 3. |
| PMID 18388178 |
| Status of minimal residual disease testing in childhood haematological malignancies. |
| Campana D. |
| Br J Haematol. 2008a Nov;143(4):481-9. Epub 2008 Aug 15. |
| PMID 18710378 |
| Molecular determinants of treatment response in acute lymphoblastic leukemia. |
| Campana D. |
| Hematology Am Soc Hematol Educ Program. 2008b:366-73. |
| PMID 19074112 |
| Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. |
| Flohr T, Schrauder A, Cazzaniga G, Panzer-Grumayer R, van der Velden V, Fischer S, Stanulla M, Basso G, Niggli FK, Schafer BW, Sutton R, Koehler R, Zimmermann M, Valsecchi MG, Gadner H, Masera G, Schrappe M, van Dongen JJ, Biondi A, Bartram CR. |
| Leukemia. 2008 Apr;22(4):771-82. Epub 2008 Jan 31. |
| PMID 18239620 |
| Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. |
| Holowiecki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Piatkowska-Jakubas B, Paluszewska M, Seferynska I, Lewandowski K, Kielbinski M, Czyz A, Balana-Nowak A, Krol M, Skotnicki AB, Jedrzejczak WW, Warzocha K, Lange A, Hellmann A. |
| Br J Haematol. 2008 May 19. |
| PMID 18492099 |
| Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. |
| Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, Soneji S, Green J, Colman S, Piacibello W, Buckle V, Tsuzuki S, Greaves M, Enver T. |
| Science. 2008 Jan 18;319(5861):336-9. |
| PMID 18202291 |
| Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. |
| Paganin M, Zecca M, Fabbri G, Polato K, Biondi A, Rizzari C, Locatelli F, Basso G. |
| Leukemia. 2008 Dec;22(12):2193-200. Epub 2008 Aug 28. |
| PMID 18754029 |
| Minimal residual disease in acute lymphoblastic leukemia. |
| Campana D. |
| Semin Hematol. 2009 Jan;46(1):100-6. |
| PMID 19100372 |
| Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children's oncology group. |
| J Clin Oncol. 2009a Jul 20;27(21):3533-9. Epub 2009 Jun 22. |
| Coustan-Smith E, Sandlund JT, Perkins SL, Chen H, Chang M, Abromowitch M, Campana D. |
| PMID 19546402 |
| Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. |
| Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, Cheng C, Su X, Rubnitz JE, Basso G, Biondi A, Pui CH, Downing JR, Campana D. |
| Lancet Oncol. 2009b Feb;10(2):147-56. Epub 2009 Jan 13. |
| PMID 19147408 |
| Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). |
| Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Rossi G, Borlenghi E, Pogliani EM, Terruzzi E, Fabris P, Cassibba V, Lambertenghi-Deliliers G, Cortelezzi A, Bosi A, Gianfaldoni G, Ciceri F, Bernardi M, Gallamini A, Mattei D, Di BE, Romani C, Scattolin AM, Barbui T, Rambaldi A. |
| Blood. 2009 Apr 30;113(18):4153-62. Epub 2009 Jan 13. |
| PMID 19141862 |
| Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. |
| Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, Harvey RC, Chen IM, Clifford RJ, Carroll WL, Reaman G, Bowman WP, Devidas M, Gerhard DS, Yang W, Relling MV, Shurtleff SA, Campana D, Borowitz MJ, Pui CH, Smith M, Hunger SP, Willman CL, Downing JR. |
| N Engl J Med. 2009 Jan 29;360(5):470-80. Epub 2009 Jan 7. |
| PMID 19129520 |
| Treating childhood acute lymphoblastic leukemia without cranial irradiation. |
| Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Coustan-Smith E, Kun LE, Jeha S, Cheng C, Howard SC, Simmons V, Bayles A, Metzger ML, Boyett JM, Leung W, Handgretinger R, Downing JR, Evans WE, Relling MV. |
| N Engl J Med. 2009 Jun 25;360(26):2730-41. |
| PMID 19553647 |
| Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. |
| van der Velden V, Corral L, Valsecchi MG, Jansen MW, De LP, Cazzaniga G, Panzer-Grumayer ER, Schrappe M, Schrauder A, Meyer C, Marschalek R, Nigro LL, Metzler M, Basso G, Mann G, den Boer ML, Biondi A, Pieters R, van Dongen JJ. |
| Leukemia. 2009 Jun;23(6):1073-9. Epub 2009 Feb 12. |
| PMID 19212338 |
| Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. |
| Yang JJ, Cheng C, Yang W, Pei D, Cao X, Fan Y, Pounds SB, Neale G, Trevino LR, French D, Campana D, Downing JR, Evans WE, Pui CH, Devidas M, Bowman WP, Camitta BM, Willman CL, Davies SM, Borowitz MJ, Carroll WL, Hunger SP, Relling MV. |
| JAMA. 2009 Jan 28;301(4):393-403. |
| PMID 19176441 |
| Contributor(s) |
| Written | 07-2009 | Dario Campana |
| Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis TN 38105, USA |
| Citation |
| This paper should be referenced as such : |
| Campana D
. Detection of minimal residual disease in acute lymphoblastic leukemia
. Atlas Genet Cytogenet Oncol Haematol. July 2009 . URL : http://AtlasGeneticsOncology.org/Deep/MDRinALLID20063.htm l |
| © Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Mon Sep 7 12:36:47 CEST 2009 |
For comments and suggestions or contributions, please contact us